For injectable formulations, this can be complex because manufacturers must prove their products work identically to the original subcutaneous semaglutide formulations
Safety concerns come with this wider use
Common side effects include: Nausea Vomiting Constipation Abdominal discomfort or pain Many of these occur during dose escalation, which is why the Phase 2 trial tested different starting doses
Compared to lower doses and the competitors, 14 mg of oral semaglutide demonstrated superior and clinically meaningful benefits in glycemic control and body weight loss [6, 8, 12,13,14,15]
Switching to a different GLP-1 receptor agonist eliminated the nodules entirely over a five-month follow-up period
Chnh v vy C Ph ng Bi ra i vi mong mun gip mi ngi c c hi s dng ng c ph cht lng vi mc gi hp l nht